Back to search

National and Kapodistrian University of Athens

Μοριακή ανίχνευση της έκφρασης του γονιδίου survivin στο αίμα ασθενών με πρωτοπαθές μελάνωμα δέρματος

Abstract

dc:description

Melanoma is a type of cancer that develops from the pigment-containing cells known as melanocytes that has a high metastatic potential and can metastasize via blood vessels or lymphatic routes to every organ and site in the body. Malignant melanoma is one of the most aggressive malignancies in humans and is responsible for almost 60% of lethal skin tumors. With conventional therapies is the prognosis for patients with metastatic melanoma poor. Therefore, early diagnosis, accurate staging and appropriate therapy are essential for increasing life expectancy of melanoma patients. Prognosis of melanoma patients is based on histological data and the clinical image of the patients leading to misdiagnosis and downstaged subjects. The TNM staging system used for the melanoma classification cannot though always accurately determine the prognosis and appropriate treatment for melanoma patients, as for example it cannot always distinguish between 'good prognosis' and 'poor prognosis' tumours for patients with the same tumor-stage but diverse clinical behavior. On the demand of new tumor markers for the better screening of melanoma patients and the determination of appropriate therapeutic approaches, survivin could play a significant role. Through a wide gamut of interactions with various signal transduction pathways and interference in the apoptotic process, survivin exerts tumor-propagation actions. This molecule is not only responsible for increased cancer-cell survival and proliferation, but also enables in cancer cells a highly metastatic potential and therapy-evasion properties. The era of translational medicine dictates the development of drug-targeted cancer therapies without severe systemic adverse reactions. Survivin is considered as a rational target in the “fight” against cancer, due to its presence in virtually every tumor and its absence from most finally differentiated adult tissues. The administration of survivin-targeted agents, alone or in combination with conventional therapeutic measures, may contribute to the renovation of our therapeutic arsenarium against cancer.The aim of the present study was to determine the differences of the expression level of survivin protein in correlation with the tumor stage as well as the correlation between survivin expression levels and the overall- and progression-free survival. For the study of survivin protein expression the method of real-time PCR was applied in the peripheral blood of 64 patients with malignant melanoma and 40 normal blood donors. In this study were mainly involved patients with stage III and IV melanoma. According to the results of the study the rates of the survivin expression are higher in the peripheral blood of melanoma patients compared to the rates of survivin levels expressed in peripheral blood of healthy donors and this is in accordance with the literature. The survivin expression levels have shown extreme deviations in the group of patients, while the difference in the expression level of survivin in the blood between stage III and stage IV patients was not statistically significant. Comparing the overall survival as well as the diasease-free survival rates between stage III and IV patients, it has been shown that disease stage is an independent prognostic factor for overall and disease-free survival. The survivin expression levels do not exhibit statistically significant correlation with the overall survival of the patients. A statistically significant correlation was found though between survivin expression levels and relaps. More precisely patients with lower protein expression relapsed earlier than those with higher survivin expression. This last finding is not consistent with the existing literature, regarding a significant association between figh survivin expression levels and terminal stages, rapid disease progression and poor overall survival of patients with hematologic malignancies or solid tumors. This finding could possibly be related to the fact that tis statistical analysis took into consideration separately the diasease stage which is an independent prognostic factor.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Athanasoula, Kalliopi
  • Αθανασούλα, Καλλιόπη

Subjects

dc:subject × 7

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40501

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Athanasoula, Kalliopi; Αθανασούλα, Καλλιόπη. Μοριακή ανίχνευση της έκφρασης του γονιδίου survivin στο αίμα ασθενών με πρωτοπαθές μελάνωμα δέρματος. National and Kapodistrian University of Athens, 2017. http://hdl.handle.net/10442/hedi/40501